Postmarket Clinical Follow-up Study to Confirm the Performance of the Wearable Pulse-Oximeter BrOxy M (SOMBRERO)

NCT ID: NCT04810221

Last Updated: 2022-04-20

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-24

Study Completion Date

2021-04-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a post market clinical follow up study performed to confirm the performance of BrOxy M pulse oximeter in comparison with a reference, CE marked, pulse oximeter equipment in a controlled desaturation study over a range between 80% and 100% peripheral oxygen saturation (SpO2).

The study will be performed on a group of healthy volunteers in a controlled clinical setting.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a post market clinical follow up study performed to confirm the performance of BrOxy M pulse oximeter in comparison with a reference, CE marked, pulse oximeter equipment (Nellcor™ Bedside Respiratory Patient Monitoring System model PM1000N, Covidien LLC, USA) in a controlled desaturation study over a range between 80% and 100% SpO2.

The study will be performed on a group of healthy volunteers in a controlled clinical setting. Due to the use of a controlled desaturation protocol foreseen by the standard ISO 80601-2-61:2017, this study is classified as an interventional post-market clinical study in accordance with Annex I of EN ISO 14155:2020.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Laboratory Testing on Healthy Volunteers to Verify SpO2 and Heart Rate (HR) Accuracy of BrOxy M

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental

Measure of SpO2 and HR obtained in enrolled subjects using BrOxy M and a reference pulse oximeter in paired observations

Group Type EXPERIMENTAL

Controlled desaturation study

Intervention Type OTHER

Measure of SpO2 and Heart Rate by BrOxy M device and reference device in a controlled desaturation study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Controlled desaturation study

Measure of SpO2 and Heart Rate by BrOxy M device and reference device in a controlled desaturation study.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy subjects of both sexes with an age ≥ 18 and ≤ 50.
2. American Society of Anesthesiology (ASA) classification 1
3. Positive Allen's test
4. Intact and healthy skin on the selected wrist
5. Wrist circumference diameter between 150 mm e 200 mm.
6. Normal electrocardiogram (ECG) obtained at screening or within 2 months prior to screening
7. Ability to understand and execute the required study procedures and provide an informed consent to the study

Exclusion Criteria

1. Presence of at least one of the following altered hemoglobin parameters at screening:

1. Alpha-hemoglobin (αHb) ≤ 10 gr/dl
2. Carboxy-hemoglobin (COHb) ≥ 3%
3. Methaemoglobin (MetHb) ≥ 2%
2. For pre-menopausal female subjects only: positive pregnancy test performed at screening on urines or capillary blood
3. Presence of any cardiovascular pathology in medical history.
4. Any episodes of respiratory infection during the 30 days prior to screening
5. Any prior experience of Dyspnea
6. Hospitalization during the 2 months prior to screening, for any reason.
7. Chronic drug intake known to interfere with gaseous exchanges or induce changes in cardiac frequency
8. Presence of any medical condition not allowing the subject to perform the required test
9. Known allergy to adhesive tapes
10. Participation in an interventional study with a medicinal product or a medical device in the 30 days prior to screening.
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Life Meter srl

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stefano Marinari, Medicine

Role: PRINCIPAL_INVESTIGATOR

Ospedale "SS. Annunziata", Via dei Vestini, 66100 Chieti, Italy

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ospedale "SS. Annunziata"

Chieti, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

01M2020-CH.LMD

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Alar SpO2 Sensor Study
NCT06398262 COMPLETED